Defining the mechanisms of action of drug candidates that can reactivate latent proviruses presents formidable challenges both because studies ofthe physiological mechanisms responsible for proviral reactivation are incomplete and because there are no universally accepted primary cell models for HIV and SIV latency that can be used to support the development of new drugs. This project has been designed to address these critical Collaboratory strategic needs by defining how the sequential activation of multiple signaling pathways modifies the duration and magnitude ofthe HIV transcriptional response in primary cell models for HIV latency and by defining the role of the accessory protein Nef in establishing and maintaining HIV and SIV latency. We hypothesize that sustained HIV proviral reactivation minimally requires both the activation of P-TEFb and the sequential activation of NF-Kappa B, NFAT and AP-1. As part of our further development ofthe primary cell model we have recently made the surprising and discovery that proviral silencing is strongly enhanced in cells infected with viruses expressing Nef. We hypothesize that disruption of cell signaling pathways by Nef creates an environment that promotes viral entry into latency. Since Nef has long been known to enhance viral replication and spread, the obsen/ation that Nef also increases the frequency of HIV silencing raises the intriguing possibility that proviral latency is an important mechanism used to disseminate viruses eariy during infections and to escape the strong immune responses mounted during acute infections. In the course of these studies we will be interacting closely with other Collaboratory investigators. Key interactions will include the detailed evaluation of candidate drugs in our pipeline (Hazuda), development of latency models in primary cells (Planelles), development of latency models for SIV (Clements), and evaluation of new cellijlar factors that contribute to the maintenance of HIV latency (Greene, Verdin, Ofi and Peteriin).
This proposal forms an integral part ofthe basic science program ofthe Collaboratory. Specifically, the proposal will develop new techniques for evaluating drug candidates and explore an unexpected mechanism involving HIV Nef that forces HIV entry into latency.
|Honeycutt, Jenna B; Sheridan, Patricia A; Matsushima, Glenn K et al. (2015) Humanized mouse models for HIV-1 infection of the CNS. J Neurovirol 21:301-9|
|King, Helen L; Keller, Samuel B; Giancola, Michael A et al. (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav 18:1722-5|
|Manson McManamy, Mary E; Hakre, Shweta; Verdin, Eric M et al. (2014) Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother 23:145-9|
|Duverger, Alexandra; Wolschendorf, Frank; Anderson, Joshua C et al. (2014) Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol 88:364-76|
|Spivak, Adam M; Andrade, Adriana; Eisele, Evelyn et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58:883-90|
|Denton, Paul W; Long, Julie M; Wietgrefe, Stephen W et al. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10:e1003872|
|Abreu, Celina M; Price, Sarah L; Shirk, Erin N et al. (2014) Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9:e97257|
|Archin, Nancie M; Margolis, David M (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27:29-35|
|Liu, Pingyang; Xiang, Yanhui; Fujinaga, Koh et al. (2014) Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289:9918-25|
|Persaud, Deborah; Patel, Kunjal; Karalius, Brad et al. (2014) Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 168:1138-46|
Showing the most recent 10 out of 77 publications